Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM presurgical trial in luminal breast cancer/DCIS
2021-000134-34Phase 2Active
- Sponsor
- Ospedali Galliera
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of metformin in breast cancer and ductal carcinoma in situ (DCIS) (2 arms), sponsored by Ospedali Galliera. Primary endpoint: Interim dose-limiting toxicity frequency. Started Jun 2021; status: active.
02
Drugs
metformin
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on 2021-000134-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000134-34.